In conclusion, our study identifies a novel and clinically relevant regulatory axis in metastatic prostate cancer, wherein BET family proteins—particularly BRD4—function as central epigenetic effectors of the H19/cell adhesion molecule circuitry. This evidence concerns the gene H19 and prostate cancer.